BIND, Amgen collaborate on solid tumor drug development

01/9/2013 | American City Business Journals

Amgen and BIND Biosciences agreed to develop a drug for solid tumors using the latter's technology platform. The partners hope to develop a new class of drug that would be more effective and less toxic than existing chemotherapy treatments. BIND could potentially receive up to $180.5 million in upfront and milestone fees, plus royalties.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC